The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
Official Title: A Phase 2 Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
Study ID: NCT01263899
Brief Summary: This is a Phase 2 study to assess the efficacy of SB1518 in the treatment of patients with advanced lymphoid malignancies including Hodgkin Lymphoma, Mantle Cell Lymphoma and Indolent Lymphoma (follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma and small lymphocytic lymphoma).
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of Nebraska Medical Center, Omaha, Nebraska, United States
Weill Medical College of Cornell, New York, New York, United States
University of Rochester James P. Wilmot Cancer Center, Rochester, New York, United States
MD Anderson Cancer Canter, Houston, Texas, United States
University of British Columbia, Vancouver, British Columbia, Canada
Name: Anas Younes, MD
Affiliation: MD Anderson Cancer Center at University of Texas, Houston
Role: PRINCIPAL_INVESTIGATOR
Name: Jonathan Friedberg, MD
Affiliation: University of Rochester James P. Wilmot Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Name: Peter Martin, MD
Affiliation: Weill Medical College of Cornell University
Role: PRINCIPAL_INVESTIGATOR
Name: Julie Vose, MD
Affiliation: University of Nebraska
Role: PRINCIPAL_INVESTIGATOR
Name: Richard Klasa, MD
Affiliation: British Columbia Cancer Center - Vancouver Centre
Role: PRINCIPAL_INVESTIGATOR